Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
After a failed merger with Walgreens Boots Alliance Inc (NASDAQ:WBA) and the termination of a merger agreement with Albertsons, one Wall Street analyst says Rite Aid Corporation (NYSE:RAD) is now in an extremely difficult competitive position and will likely continue to struggle in the market.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Goldman Sachs analyst Robert Jones resumed coverage of Rite Aid with a Sell rating and $1 price target.
The Thesis
A standalone Rite Aid simply doesn’t have the resources to effectively compete, Jones said.
“We expect RAD’s smaller footprint will hamper it from participating in the continued growth of preferred/narrow networks in Part D and commercial plans, where store breadth is essential to getting in network and pricing competitively,” Jones wrote in a note.
He said this trend has already been playing out in recent years. Since 2013 Rite Aid’s same-store prescription growth has been roughly flat. In that same time, Walgreens and CVS Health Corp (NYSE:CVS) have been growing same-store prescriptions by 4.5 percent and 3.9 percent, respectively.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The only silver lining for Rite Aid investors is that the stock trades at a slight forward EV/EBITDA multiple discount to its peers. However, Jones said that discount is justified given Rite Aid’s relatively weak revenue and margin growth profile.
For now, Goldman doesn’t see a light at the end of the tunnel. Jones said EBITDA declines have continued since Rite Aid’s asset sales in late 2017 and he sees no indication that trend will reverse any time soon.
Price Action
Rite Aid traded lower by 4 percent Thursday to $1.30 per share.
Related Links:
M&Ain't: Several Of The Year's Biggest Mergers Face Uncertain Future
Two Major Mergers Fall Through, A Reminder That Deals Don't Always Work Out
Photo credit: Mike Mozart, Flickr
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.